HLA-G expression in melanoma: A way for tumor cells to escape from immunosurveillance

被引:382
作者
Paul, P
Rouas-Freiss, N
Khalil-Daher, I
Moreau, P
Riteau, B
Le Gal, FA
Avril, MF
Dausset, J
Guillet, JG
Carosella, ED
机构
[1] Hop St Louis, Ctr Hayem, CEA,Dept Rech Med, Serv Rech Hematoimmunol,Direct Sci Vivant, F-75010 Paris, France
[2] Univ Paris 05, Inst Cochin Genet Mol, Lab Immunol Pathol Infect & Tumorales, INSERM,U445, F-75270 Paris 06, France
[3] Inst Gustave Roussy, Serv Dermatol, F-94805 Villejuif, France
[4] Fdn Jean Dausset, Ctr Etud Polymorphisme Humain, F-75010 Paris, France
关键词
D O I
10.1073/pnas.95.8.4510
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Considering the well established role of non-classical HLA-G class I molecules in inhibiting natural killer (NK) cell function, the consequence of abnormal HLA-G expression in malignant cells should be the escape of tumors from immunosurveillance. To examine this hypothesis, we analyzed HLA-G expression and NK sensitivity in human malignant melanoma cells. Our analysis of three melanoma cell lines and ex vivo biopsy demonstrated that (i) IGR and M74 human melanoma cell lines exhibit a high level of HLA-G transcription with differential HLA-G isoform transcription and protein expression patterns, (ii) a higher level of HLA-G transcription ex vivo is detected in a skin melanoma metastasis biopsy compared with a healthy skin fragment from the same individual, and (iii) HLA-G protein isoforms other than membrane-bound HLA-G1 protect IGR from NK lysis. It thus appears of critical importance to consider the specific role of HLA-G expression in tumors in the design of future cancer immunotherapies.
引用
收藏
页码:4510 / 4515
页数:6
相关论文
共 39 条
[1]  
BODMER WF, 1993, ANN NY ACAD SCI, V690, P42
[2]   TRANSCRIPTION ANALYSIS OF CLASS-II HUMAN-LEUKOCYTE ANTIGEN GENES FROM NORMAL AND IMMUNODEFICIENT LYMPHOCYTES-B, USING POLYMERASE CHAIN-REACTION [J].
BULL, M ;
VANHOEF, A ;
GORSKI, J .
MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (07) :3792-3796
[3]  
BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1
[4]   HLA-G revisited [J].
Carosella, ED ;
Dausset, J ;
Kirszenbaum, M .
IMMUNOLOGY TODAY, 1996, 17 (09) :407-409
[5]   Alternative promoters of gene MAGE4a [J].
DePlaen, E ;
Naerhuyzen, B ;
DeSmet, C ;
Szikora, JP ;
Boon, T .
GENOMICS, 1997, 40 (02) :305-313
[6]   The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation [J].
DeSmet, C ;
DeBacker, O ;
Faraoni, I ;
Lurquin, C ;
Brasseur, F ;
Boon, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (14) :7149-7153
[7]   DOES PREGNANCY INFLUENCE THE PROGNOSIS OF MALIGNANT-MELANOMA [J].
DRISCOLL, MS ;
GRINJORGENSEN, CM ;
GRANTKELS, JM .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1993, 29 (04) :619-630
[8]   Implications for immunosurveillance of altered HLA class I phenotypes in human tumours [J].
Garrido, F ;
RuizCabello, F ;
Cabrera, T ;
PerezVillar, JJ ;
LopezBotet, M ;
DugganKeen, M ;
Stern, PL .
IMMUNOLOGY TODAY, 1997, 18 (02) :89-95
[9]   DEPENDENCE OF PEPTIDE BINDING BY MHC CLASS-I MOLECULES ON THEIR INTERACTION WITH TAP [J].
GRANDEA, AG ;
ANDROLEWICZ, MJ ;
ATHWAL, RS ;
GERAGHTY, DE ;
SPIES, T .
SCIENCE, 1995, 270 (5233) :105-108
[10]  
HOULIHAN JM, 1992, J IMMUNOL, V149, P668